The FDA approved 2 renal denervation devices. There are still questions about who will benefit.

MedTech Dive December 13, 2023
Elise Reuter

The devices from Recor and Medtronic are intended to treat high blood pressure. An advisory panel backed the former, but recommended against approval of the latter.

The Food and Drug Administration recently approved two hypertension treatments made by Recor and Medtronic, opening a new market that Medtronic has estimated at more than $1 billion. The procedure, called renal denervation, is intended to offer an alternative for patients who have tried medications and lifestyle changes to reduce their blood pressure.

Questions about efficacy and who benefits most from the treatments could be hurdles to adoption as both companies seek insurance coverage.

A long road to approval

Medical device companies have been working for more than a decade to bring a...

Today's Sponsors

Today's Sponsor